Compare Elder Pharma with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs CIPLA - Comparison Results

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA CIPLA ELDER PHARMA/
CIPLA
 
P/E (TTM) x -0.2 23.1 - View Chart
P/BV x 0.1 2.4 4.3% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 ELDER PHARMA   CIPLA
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
CIPLA
Mar-19
ELDER PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs380678 56.0%   
Low Rs188484 38.9%   
Sales per share (Unadj.) Rs491.2198.2 247.8%  
Earnings per share (Unadj.) Rs-3.218.5 -17.2%  
Cash flow per share (Unadj.) Rs14.435.0 41.2%  
Dividends per share (Unadj.) Rs03.00 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs376.5186.3 202.1%  
Shares outstanding (eoy) m20.54805.70 2.5%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.62.9 19.7%   
Avg P/E ratio x-89.331.4 -284.6%  
P/CF ratio (eoy) x19.716.6 118.7%  
Price / Book Value ratio x0.83.1 24.2%  
Dividend payout %016.2 0.0%   
Avg Mkt Cap Rs m5,833468,031 1.2%   
No. of employees `000NA22.6 0.0%   
Total wages/salary Rs m2,17928,565 7.6%   
Avg. sales/employee Rs ThNM7,053.1-  
Avg. wages/employee Rs ThNM1,261.5-  
Avg. net profit/employee Rs ThNM659.1-  
INCOME DATA
Net Sales Rs m10,089159,710 6.3%  
Other income Rs m2574,766 5.4%   
Total revenues Rs m10,346164,475 6.3%   
Gross profit Rs m-79230,973 -2.6%  
Depreciation Rs m36113,263 2.7%   
Interest Rs m2,7561,684 163.6%   
Profit before tax Rs m-3,65320,791 -17.6%   
Minority Interest Rs m0-172 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m1255,695 2.2%   
Profit after tax Rs m-6514,924 -0.4%  
Gross profit margin %-7.819.4 -40.5%  
Effective tax rate %-3.427.4 -12.5%   
Net profit margin %-0.69.3 -6.9%  
BALANCE SHEET DATA
Current assets Rs m9,240124,266 7.4%   
Current liabilities Rs m9,99837,715 26.5%   
Net working cap to sales %-7.554.2 -13.9%  
Current ratio x0.93.3 28.1%  
Inventory Days Days4691 51.1%  
Debtors Days Days6095 63.2%  
Net fixed assets Rs m10,124105,190 9.6%   
Share capital Rs m2061,611 12.8%   
"Free" reserves Rs m5,582148,511 3.8%   
Net worth Rs m7,734150,123 5.2%   
Long term debt Rs m4,88938,301 12.8%   
Total assets Rs m22,882239,633 9.5%  
Interest coverage x-0.313.3 -2.4%   
Debt to equity ratio x0.60.3 247.8%  
Sales to assets ratio x0.40.7 66.2%   
Return on assets %11.86.9 169.7%  
Return on equity %-0.89.9 -8.5%  
Return on capital %22.311.8 188.5%  
Exports to sales %3.034.7 8.8%   
Imports to sales %0.40-   
Exports (fob) Rs m30755,419 0.6%   
Imports (cif) Rs m43NA-   
Fx inflow Rs m30757,410 0.5%   
Fx outflow Rs m12519,041 0.7%   
Net fx Rs m18138,368 0.5%   
CASH FLOW
From Operations Rs m11,75416,911 69.5%  
From Investments Rs m-561-16,687 3.4%  
From Financial Activity Rs m-6,762-3,487 193.9%  
Net Cashflow Rs m4,432-3,451 -128.4%  

Share Holding

Indian Promoters % 39.6 16.0 247.5%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 7.5 12.2 61.5%  
FIIs % 16.8 23.7 70.9%  
ADR/GDR % 0.0 1.1 -  
Free float % 36.1 26.2 137.8%  
Shareholders   16,479 161,166 10.2%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   DISHMAN PHARMA  CADILA HEALTHCARE  VENUS REMEDIES  PANACEA BIOTECH  GLENMARK PHARMA  

Compare ELDER PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Extend Gains; Tata Motors & ONGC Climb 5%(12:30 pm)

Share markets in India have extended early morning gains and are presently trading higher. Investors are cautious ahead of the release of Consumer Price Index-based inflation.

Related Views on News

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY19); Net Profit Up 144.0% (Quarterly Result Update)

May 24, 2019 | Updated on May 24, 2019

For the quarter ended March 2019, CIPLA has posted a net profit of Rs 4 bn (up 144.0% YoY). Sales on the other hand came in at Rs 44 bn (up 19.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (3QFY19); Net Profit Up 17.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, CIPLA has posted a net profit of Rs 3 bn (up 17.5% YoY). Sales on the other hand came in at Rs 40 bn (up 2.4% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (2QFY19); Net Profit Down 15.8% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, CIPLA has posted a net profit of Rs 4 bn (down 15.8% YoY). Sales on the other hand came in at Rs 40 bn (down 1.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

What if Indiabulls Housing Finance and Yes Bank Do Not Rebound?(Profit Hunter)

Oct 1, 2019

How long should you wait for fallen blue chips like Yes Bank and Indiabulls Housing Finance to rebound?

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

Foreign Money is Chasing Indian Stocks Once Again(The 5 Minute Wrapup)

Oct 4, 2019

Around Rs 75 billion poured into the Indian stock market in the month of September.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 8-QTR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS